Neovacs has received a first payment of a total amount up to €702.000, for its preclinical development program AllergyVacs, within the grant awarded by the National Agency for Research (ANR), conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute.
Sanofi and Regeneron Pharmaceuticals said they will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases.
Allergy Therapeutics has begin its G205 Phase II study to check the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy. It will be used to treat the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
Allergy Therapeutics, a pharmaceutical company specialising in allergy vaccines, has announced positive results from preclinical research of its therapeutic peanut allergy vaccine, Polyvac Peanut.
The Walloon (Belgium) government has decided to fund its ASIT Biotech to help develop new drug candidates to treat the main food allergies caused by peanuts, cow’s milk and egg whites.